Ascletis bets on once-monthly ASC36 to fight obesity
October 30, 2025 | 15:15
Ascletis Pharma Inc. announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical development candidate.
Mobile Version